SynthesisBMJ open2026
Follow-up colonoscopy after abnormal stool-based colorectal cancer screening: a systematic review of completion, timeliness and implementation strategies.
Synthesis in BMJ open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo synthesise evidence on diagnostic colonoscopy completion and time-to-colonoscopy after abnormal stool-based colorectal cancer screening tests and to examine the implementation strategies and health-system configurations used to support follow-up.
designSystematic review with narrative synthesis, reported in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses 2020 statement and the Synthesis Without Meta-analysis reporting guideline. DATA SOURCES: We searched MEDLINE via PubMed, Embase via Ovid and Scopus for articles published from 1 January 2010 to 28 October 2025. Reference lists of included studies were also screened. ELIGIBILITY CRITERIA: Randomised and non-randomised trials, observational studies, mixed-methods studies and eligible programme evaluations involving adults with an abnormal faecal immunochemical test, guaiac faecal occult blood test or multitarget stool DNA-faecal immunochemical test were included. Eligible studies reported diagnostic colonoscopy completion, time to colonoscopy or implementation-related outcomes. DATA EXTRACTION AND SYNTHESIS: Study characteristics, implementation strategies, colonoscopy completion, time-to-colonoscopy and sociodemographic differences were extracted using a piloted form. Risk of bias was assessed using the Revised Cochrane risk-of-bias tool for randomised trials, the Risk of Bias in Non-randomised Studies of Interventions or the Joanna Briggs Institute tools, according to study design. Certainty of evidence was assessed using Grading of Recommendations, Assessment, Development and Evaluation (GRADE). Because of differences in settings, study designs and outcome definitions, findings were synthesised narratively. Reported follow-up intervals were grouped into approximately ≤3, ≤6 and ≤12 months.
resultsTwenty-five studies were included, predominantly from high-income settings. Colonoscopy completion within 6-12 months commonly ranged from approximately 30% to 55% in federally qualified health centres and safety-net settings to 70%-80% or higher in organised and integrated programmes. Time to colonoscopy ranged from approximately 42 to 184 days. Higher completion and shorter delays were more commonly reported in programmes combining real-time tracking, clearly assigned responsibility, proactive outreach or navigation and coordinated colonoscopy scheduling. Of the 25 studies, 1 was judged to have low overall risk of bias, 19 moderate risk and 5 serious risk. Certainty of evidence was low for colonoscopy completion at approximately 6 and 12 months and very low for approximately 3-month completion and time to colonoscopy.
conclusionsHigher-performing post-abnormal-test pathways commonly incorporated registry-based tracking, clear ownership of abnormal results, proactive outreach or navigation and coordinated access to colonoscopy. However, confidence in the comparative performance of specific implementation bundles is limited by heterogeneous and predominantly observational evidence. Health systems serving under-resourced populations may require targeted investment in tracking, navigation and integrated scheduling to improve timely and equitable follow-up. PROSPERO REGISTRATION NUMBER: PROSPERO CRD42024579672.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.